Clinical Trial of Quantitative Real-Time Polymerase Chain Reaction for Detection of Cytomegalovirus in Peripheral Blood of Allogeneic Hematopoietic Stem-Cell Transplant Recipients

54Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The preemptive therapy of cytomegalovirus (CMV) reactivation is useful for the prevention of CMV disease in allogeneic hematopoietic stem-cell transplant (HSCT) recipients. We compared results of the pp65 CMV antigenemia test with quantitative touch-down polymerase chain reaction (Q-PCR) on unfractionated whole blood for the detection of CMV reactivation in 51 HSCT recipients. Forty episodes of reactivation in 28 patients were detected by antigenemia and treated by antiviral drugs. Q-PCR detected CMV DNA in 39 (97.5%) of 40 reactivation episodes. False-positive results occurred in 3% of tests, of which 63% were borderline positive. Q-PCR results were positive earlier than antigenemia results in 30 (77%) of 39 episodes detected by antigenemia. Q-PCR remained positive after treatment was discontinued in 14 (36%) of 39 episodes and predicted the return of CMV reactivation in 4 (31%) of 13 episodes. Q-PCR was more sensitive than the antigenemia test and had sufficient specificity for clinical use.

Cite

CITATION STYLE

APA

Cortez, K. J., Fischer, S. H., Fahle, G. A., Calhoun, L. B., Childs, R. W., Barrett, A. J., & Bennett, J. E. (2003). Clinical Trial of Quantitative Real-Time Polymerase Chain Reaction for Detection of Cytomegalovirus in Peripheral Blood of Allogeneic Hematopoietic Stem-Cell Transplant Recipients. Journal of Infectious Diseases, 188(7), 967–972. https://doi.org/10.1086/378413

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free